Quantum BioPharma Ltd.

NasdaqCM:QNTM Stock Report

Market Cap: US$21.4m

Quantum BioPharma Dividends and Buybacks

Dividend criteria checks 0/6

Quantum BioPharma does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-27.5%

Buyback Yield

Total Shareholder Yield-27.5%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Seeking Alpha • Sep 29

FSD Pharma receives Nasdaq minimum bid price deficiency notification

FSD Pharma (NASDAQ:HUGE) received Nasdaq notification stating the company is not in compliance with the minimum bid price requirement.  The company’s class B subordinate voting shares has not maintained a minimum bid price of $1.00/share for the 30 consecutive business days from August 15, 2022 to September 26, 2022. The company has been provided 180 calendar days, or until March 27, 2023, to regain compliance. If the company does not regain compliance by March 27, 2023, the company may be eligible for additional time to regain compliance or may face delisting from Nasdaq.
Seeking Alpha • Sep 06

FSD Pharma gets clearance to start phase 2 trial of FSD201 in US, Canada

FSD Pharma (NASDAQ:HUGE) received clearance from the U.S. Food and Drug Administration (FDA) and Health Canada to start a phase 2 trial of FSD201 to treat nociplastic pain associated with idiopathic mast cell activation (IMCA) syndrome. Mast cell activation syndrome causes mast cells to release an abnormal amount of chemicals into the body, which causes allergy symptoms and other symptoms. The company noted that FSD201 has shown to be safe and well tolerated in a phase 1 trial. "We are working with our clinical sites in the U.S. and Canada to initiate the study and intend to release more details on the study very soon, said Lakshmi Kotra, CEO of FSD Pharma unit Lucid Psycheceuticals.

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if QNTM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QNTM's dividend payments have been increasing.

Dividend Yield vs Market

Quantum BioPharma Dividend Yield vs Market
How does QNTM dividend yield compare to the market?
SegmentDividend Yield
Company (QNTM)n/a
Market Bottom 25% (US)1.3%
Market Top 25% (US)4.1%
Industry Average (Pharmaceuticals)1.9%
Analyst forecast (QNTM) (up to 3 years)n/a

Notable Dividend: Unable to evaluate QNTM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate QNTM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate QNTM's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as QNTM has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 15:09
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Quantum BioPharma Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaBrookline Capital Markets
Karen SterlingKingswood Capital